• Patent granted by USPTO covering use of NUZ-001 in neurodegenerative diseases and cancer
• Provides protection for NUZ-001 and related compounds in US until 2039
• Strengthens commercial potential and IP estate for NUZ-001

Neurizon Therapeutics Limited (ASX: NUZ) has received a US patent for its lead drug candidate NUZ-001, covering the 'method of use' of the drug in treating mTOR pathway-related diseases, including amyotrophic lateral sclerosis/motor neurone disease (ALS/MND), Alzheimer's disease, Huntington's disease, Parkinson's disease, and cancer. The patent was granted by the United States Patent & Trademark Office (USPTO) and provides protection for NUZ-001 and structurally related compounds in the US market until 2039. This patent grant follows the company's receipt of Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for NUZ-001 in May 2024. The patent strengthens Neurizon's commercial potential and IP estate for NUZ-001 as the company advances its clinical trial pipeline. Neurizon's Managing Director and CEO, Dr. Michael Thurn, stated that the patent grant significantly strengthens the company's market positioning and provides a strong framework for future licensing negotiations. The patent application is still under review in other major regulatory jurisdictions worldwide, and Neurizon expects to report additional grants in the near future.